Asters has successfully defended the interests of Teva Pharmaceutical Industries in a dispute involving the extension of a patent term for a medical product for an additional three years.
“As a result of our work, the Supreme Court has rejected the cassation appeal of the opponents, the State Intellectual Property Service of Ukraine, and Synthon, another generic developer and producer,” Asters stated in a firm press release. According to Asters, “earlier, [our] team successfully defended Teva in the court of first instance and the Court of Appeal canceling the refusal of the Patent office to grant patent term extension.”
Asters' team working on the project was led by Co-Managing Partner Serhii Sviriba and included Counsels Taras Kyslyy and Viktoriya Podvorchanska, Senior Associate Vitaliy Kulinich, and Associate Olena Kozhokar.
